Inhibrx Inc (INBX NASDAQ) stock market data APIs
$14.4373
-0.2(-1.4%)
as of March 24, 2025
Inhibrx Inc Financial Data Overview
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Prev. Close
14.6349
Open
14.4373
High
14.9924
Low
13.9239
52 wk Range
10.8-35.42
Market Cap
213 M
P/E Ratio
0.1307
Shares Outstanding
14 476 K
Revenue
200 K
EPS
-4.47
Beta
2.877
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Inhibrx Inc data using free add-ons & libraries
Get Inhibrx Inc Fundamental Data
Inhibrx Inc Fundamental data includes:
- Net Revenue: 200 K
- EBITDA: -261 102 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: -2.885
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inhibrx Inc News
New
Inhibrx Biosciences Full Year 2024 Earnings: Beats Expectations
Inhibrx Biosciences (NASDAQ:INBX) Full Year 2024 Results Key Financial Results Net income: US$1.69b (up from US$241.4m loss in FY 2023). EPS: US$114 (up from US$20.48 loss in FY 2023). INBX Product...
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following ...
Inhibrx Prospective Colorectal Cancer Treatment Shows Encouraging Results, Trial Expansion Planned
Inhibrx Biosciences (INBX) late Tuesday released preliminary safety and efficacy data from phase 1 t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncolo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
